Ken Griffin Aspira Women'S Health Inc. Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.3 - $0.41 $16,195 - $22,133	-53,985 Reduced 76.01%	17,036 $5,000
Q3 2022 Nov 14, 2022	SELL	$0.38 - $1.07 $69,091 - $194,547	-181,820 Reduced 71.91%	71,021 $26,000
Q2 2022 Aug 15, 2022	BUY	$0.4 - $1.09 $40,290 - $109,792	100,727 Added 66.22%	252,841 $149,000
Q1 2022 May 16, 2022	SELL	$0.88 - $1.81 $41,405 - $85,164	-47,052 Reduced 23.62%	152,114 $158,000
Q4 2021 Feb 14, 2022	BUY	$1.63 - $3.43 $217,065 - $456,769	133,169 Added 201.78%	199,166 $352,000
Q3 2021 Nov 15, 2021	BUY	$3.19 - $5.48 $129,769 - $222,926	40,680 Added 160.68%	65,997 $215,000
Q4 2020 Feb 16, 2021	BUY	$3.0 - $6.71 $29,727 - $66,489	9,909 Added 64.31%	25,317 $170,000
Q3 2020 Nov 16, 2020	BUY	$2.54 - $4.56 $39,136 - $70,260	15,408 New	15,408 $48,000

431K

Ticker AWH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 124,296,000
Market Cap $123M
Description
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gyneco...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.